Physician
Pediatric Associates of Tampa Bay, LLC
Pediatric Associates of Tampa Bay, LLC was paid $10.38M by Medicaid between Jan 2018 and Feb 2024, across 74 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 25% of everything it billed.
33Billing provider infoPEDIATRIC ASSOCIATES OF TAMPA BAY, LLC
PLANTATION, FL 33324
PLANTATION, FL 33324
33aNPI1861735383assigned 04/03/2013
33bProvider typePediatrics Physician
28Total paid$10.38M
24GClaims720,898
24DCodes billed74
24AFirst – last monthJan 2018 – Feb 2024
Compared with peers
Next to other Pediatrics Physician providers in Florida
Rank by total paid#19 of 971
Median peer was paid$238K
This provider vs. median44×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,719 | $30K | |
| 2019 | 169,155 | $2.50M | |
| 2020 | 142,994 | $1.73M | |
| 2021 | 128,256 | $2.38M | |
| 2022 | 174,843 | $1.64M | |
| 2023 | 101,560 | $2.10M | |
| 2024incomplete | 371 | $12K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 25% | 49,751 | 40,105 | $2.63M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 80,812 | 59,212 | $2.20M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 18% | 26,383 | 19,871 | $1.89M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 16% | 21,735 | 16,236 | $1.69M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 8.9% | 15,666 | 11,291 | $921K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.4% | 6,615 | 4,453 | $352K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.7% | 50,522 | 38,616 | $279K |
| 99051 | <1% | 22,856 | 17,007 | $57K | |
| 90670 | <1% | 13,477 | 9,967 | $57K | |
| 90686 | <1% | 13,578 | 11,899 | $39K | |
| 90461 | <1% | 30,884 | 22,037 | $25K | |
| 99383 | <1% | 234 | 222 | $24K |
62 more codes
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,380 | $23K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 348 | $15K |
| 99460 | <1% | 319 | $13K | |
| 83655 | <1% | 7,439 | $11K | |
| 3008F | <1% | 40,287 | $10K | |
| 99188 | <1% | 2,966 | $10K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 249 | $10K |
| 99381 | <1% | 202 | $9K | |
| 90716 | <1% | 5,522 | $9K | |
| 99382 | <1% | 108 | $8K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 185 | $8K |
| 85018 | <1% | 17,290 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 512 | $6K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 206 | $6K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 705 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,616 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,188 | $4K |
| 1160F | <1% | 54,499 | $4K | |
| 90633 | <1% | 6,389 | $4K | |
| 2001F | <1% | 63,316 | $4K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 538 | $4K |
| 90707 | <1% | 5,299 | $4K | |
| 90648 | <1% | 12,699 | $3K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 15,866 | $3K |
| 90651 | <1% | 1,814 | $2K | |
| 99384 | <1% | 12 | $2K | |
| 90723 | <1% | 8,305 | $2K | |
| 3074F | <1% | 28,267 | $2K | |
| 3078F | <1% | 27,335 | $2K | |
| 96127 | <1% | 9,890 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 650 | $2K |
| 92551 | <1% | 20,347 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 549 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 59 | $1K |
| 90680 | <1% | 7,257 | $933.13 | |
| 90734 | <1% | 1,130 | $847.74 | |
| 99177 | <1% | 26,203 | $803.21 | |
| 90619 | <1% | 148 | $600.00 | |
| 90621 | <1% | 101 | $363.45 | |
| 90685 | <1% | 117 | $322.13 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 167 | $303.75 |
| 90677 | <1% | 160 | $282.89 | |
| 87081 | <1% | 678 | $254.44 | |
| 94010 | <1% | 44 | $219.15 | |
| 90696 | <1% | 398 | $202.02 | |
| 90700 | <1% | 606 | $191.81 | |
| 90715 | <1% | 254 | $162.03 | |
| 99441 | <1% | 20 | $125.05 | |
| 90697 | <1% | 568 | $125.00 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 213 | $112.52 |
| 90688 | <1% | 300 | $96.92 | |
| 81003 | <1% | 151 | $95.64 | |
| 81025 | <1% | 75 | $70.92 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 151 | $68.57 |
| 99050 | <1% | 56 | $7.57 | |
| 99000 | <1% | 1,027 | $5.74 | |
| A9150 | Non-prescription drugs | <1% | 29 | $0.01 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 14 | $0.00 |
| 99173 | 0% | 20 | $0.00 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 54 | $0.00 |
| 91307 | 0% | 35 | $0.00 | |
| 3079F | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHULMAN, PETER (PRESIDENT AND CEO)
Parent organizationSALTZMAN, TANIS, PITTELL, LEVIN AND JACOBSON, LLC
| Provider | Location | Paid |
|---|---|---|
| Saltzman, Tanis, Pittell, Levin and Jacobson | Hollywood, FL | $201.29M |
| Pediatric Associates of Northeast Florida, LLC | Plantation, FL | $7.74M |
| Saltzman, Tanis, Pittell, Levin and Jacobson, LLC | Hialeah, FL | $48K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.